Skip to main content
Download PDF
- Main
ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.
- Reardon, David A;
- Schuster, James;
- Tran, David Dinh;
- Fink, Karen L;
- Nabors, Louis B;
- Li, Gordon;
- Bota, Daniela Annenelie;
- Lukas, Rimas Vincas;
- Desjardins, Annick;
- Ashby, Lynn Stuart;
- Duic, J Paul;
- Mrugala, Maciej M;
- Werner, Andrea;
- Hawthorne, Thomas;
- He, Yi;
- Green, Jennifer A;
- Yellin, Michael Jay;
- Turner, Christopher D;
- Davis, Thomas A;
- Sampson, John H
Published Web Location
https://doi.org/10.1200/jco.2015.33.15_suppl.2009Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.